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ABSTRACT
Objective To examine the effect of oxandrolone and the
timing of pubertal induction on final height in girls with
Turner’s syndrome receiving a standard dose of growth
hormone.
Design Randomised, double blind, placebo controlled
trial.
Setting 36 paediatric endocrinology departments in UK
hospitals.
ParticipantsGirlswithTurner’ssyndromeaged7-13years
at recruitment, receiving recombinant growth hormone
therapy (10 mg/m
2/week).
Interventions Participants were randomised to
oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or
placebo from 9 years of age. Those with evidence of
ovarianfailureat12yearswerefurtherrandomisedtooral
ethinylestradiol (year1,2 µg daily;year2,4 μg daily;year
3, 4 months each of 6, 8, and 10 μg daily) or placebo;
participants who received placebo and those recruited
aftertheageof12.25yearsstartedethinylestradiolatage
14.
Main outcome measure Final height.
Results 106 participants were recruited, of whom 14
withdrew and 82/92 reached final height. Both
oxandrolone and late pubertal induction increased final
height: by 4.6 (95% confidence interval 1.9 to 7.2) cm
(P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm
(P=0.05, n=48) for late pubertal induction with
ethinylestradiol. In the 48 children who were randomised
twice, the effects on final height (compared with placebo
andearlyinductionofpuberty)ofoxandrolonealone,late
induction alone, and oxandrolone plus late induction
were similar,averaging7.1 (3.4 to 10.8) cm (P<0.001). No
cases of virilisation were reported.
Conclusion Oxandrolone had a positive effect on final
height in girls with Turner’s syndrome treated with growth
hormone, as did late pubertal induction with
ethinylestradiol at age 14 years. However, these effects
were not additive, so using both had no advantage.
Oxandrolonecould,therefore,beofferedasanalternative
to late pubertal induction for increasing final height in
Turner’s syndrome.
Trial registration Current Controlled Trials
ISRCTN50343149.
INTRODUCTION
Turner’s syndrome can be defined as absence or
abnormality of the second X chromosome in a major
cell line in a phenotypic female. The phenotype is
highly variable, but short stature and gonadal dysgen-
esis are usually present. Short stature in Turner’s syn-
drome relates to impairment of each phase of the
infancy-childhood-puberty model of growth,
1 and it
results in a mean untreated final height approximately
21cmbelowthatoftheunaffectedfemalepopulation.
2
Themainstayoftreatmentforshortstatureisrecombi-
nant growth hormone, available since 1985 and
licensed for use in Turner’s syndrome. Studies have
shown its efficacy in improving height velocity and
final height, although individual outcomes vary
markedly.
3-10
TheadjunctiveuseinTurner’ssyndromeoftheana-
bolic steroid oxandrolone remains controversial.
When given in combination with growth hormone
treatment, some studies have reported improved final
height,
61112 whereas others have reported little or no
effect.
13-15 The high doses used in early studies were
associated with virilisation,
61214 and even low doses,
as reported in a recent Dutch publication, may be
problematic.
15 These potential adverse effects must
be balanced against potential improvement in growth.
Most girls with Turner’s syndrome need oestrogen
therapy during adolescence to induce pubertal
development.
16 However, the optimal age at which to
begin remains controversial; some people advocate a
delay to extend the growth period and increase final
height,
561718whereas others have highlighted psycho-
logical problems of delaying pubertal development,
suggesting that the benefits are marginal.
19 The British
Society for Paediatric Endocrinology and Diabetes
1University of Glasgow Department
of Child Health, Royal Hospital for
Sick Children, Glasgow G3 8SJ, UK
2MRC Centre of Epidemiology for
Child Health, UCL Institute of Child
Health, London, UK
3Clinical Trials Department,
Pharmacy Department, Royal
Hospital for Sick Children,
Glasgow
4Clinical and Molecular Genetics
Unit, UCL Institute of Child Health,
London
5Department of Paediatrics,
Southampton University Hospitals
NHS Trust, Southampton, UK
6University of Cambridge
Department of Paediatrics,
Addenbrooke’sH o s p i t a l ,
Cambridge, UK
Correspondence to: M Donaldson
malcolm.donaldson@glasgow.ac.
uk
Cite this as: BMJ 2011;342:d1980
doi:10.1136/bmj.d1980
BMJ | ONLINE FIRST | bmj.com page 1 of 9recognisedtheuncertaintiesrelatingtotheuseofoxan-
droloneandtimingofpubertalinductionandsetupthe
UK Turner Study in 1999 to investigate them.
METHODS
Participants
Members of the British Society for Paediatric Endo-
crinologyandDiabetesrecruitedpatientsfrompartici-
pating paediatric endocrinology departments in UK
hospitals.Inclusioncriteriaforparticipationofpatients
were karyotype confirmed Turner’s syndrome (all
karyotypes were eligible, including mosaic), age
7-13 years, no previous growth hormone treatment or
previous treatment in the range 8.3-11.7 mg/m
2/week
infivetoseveninjectionsaweek,nopreviousoxandro-
lone and oestrogen therapy, and open epiphyses.
Exclusion criteria were major systemic illness that
might affect growth and social or psychological diffi-
culties likely to seriously impair concordance.
Study design
Wedevisedadoubleblind,placebocontrolled,rando-
misedcontrolledtrial,includingtworandomisationsin
a two by two factorial design. Figure 1 shows the flow
chart of the design and participants. A steering com-
mittee (British Society for Paediatric Endocrinology
and Diabetes Clinical Trials/Audit Group) supervised
thestudy,andanindependentdataandsafetymonitor-
ing group was established. All participants’ parents
gave written informed consent.
Randomisation and masking
The British Society for Paediatric Endocrinology and
Diabetes Clinical Trials Unit (Cambridge, UK) used
minimisation by weighted randomisation for the
study’s two randomisations.
20 Randomisation 1, to
oxandrolone or placebo, took place at age 9 years (or
at enrolment, if older) and was balanced for enrolling
centre, quarter of mid-parental height, and previous
exposure to growth hormone treatment. Randomisa-
tion 2 took place at age 12 years in girls with ovarian
failure (basal serum follicle stimulating hormone con-
centration >10 U/L), with additional minimisation for
randomisation 1, to begin oral ethinylestradiol or pla-
cebo at 12 years; the placebo group subsequently
started ethinylestradiol at 14 years. Girls with a follicle
stimulating hormone concentration below 10U/L and
a karyotype associated with preservation of ovarian
function(45,X/46,XXand45,X/47,XXX
21)(thespon-
taneouspubertygroup)werenotrandomisedatrando-
misation 2. Girls with other karyotypes were tested for
concentrations of gonadotrophin releasing hormone
and were randomised at randomisation 2 if the peak
follicle stimulating hormone concentration was above
30 U/L. Participants enrolled after the age of 12.
25 years and without spontaneous puberty (the late
group) started ethinylestradiol at 14 years.
Treatment
All participants received the growth hormone prepara-
tion of their choice at 10 mg/m
2/week in daily subcuta-
neous injections. Oral oxandrolone (SPA, Milan, Italy)
was given at 0.05 mg/kg/day, with a maximum daily
dose of 2.5 mg. Oral ethinylestradiol (UCB Pharma,
Slough, UK) was given daily as follows, regardless of
the age at starting: year 1, 2 μg; year 2, 4 μg; year 3,
four months each of 6, 8, and 10 μg. The code for ran-
domisation 2 was broken at 15 years to allow introduc-
tion of progesterone therapy: oral norethisterone
(CP Pharmaceuticals, Wrexham, UK) 5 mg daily for
five days each month.
Treatment with growth hormone and oxandrolone
continued until final height was reached. Oestrogen/
Recruited (n=106)
Randomisation 1 (n=106)
Randomisation 2 (n=60)
Withdrawn* (n=7)
Withdrawn‡ (n=7)
Still growing (n=10)
Maximum height
Randomisation 1 (n=92)
Randomisation 1+2 (n=56)
n=3
n=1
n=4
Oestrogen at
12 years (n=17)
Oestrogen at
14 years (n=17)
Oestrogen at
12 years (n=12)
Oestrogen at
14 years (n=14)
Late group†
(n=11)
Spontaneous
puberty (n=7)
Late group†
(n=10)
n=9
n=1
n=10
n=1
n=11
n=1
n=13
n=9
n=1
n=9 n=11
n=3 n=3
n=10
n=17
n=2
n=15
n=1
n=10 n=7
n=14
n=2
n=13 n=10
n=1
n=6
Spontaneous
puberty (n=11)
Oxandrolone (n=51) Placebo (n=55)
Final height
Randomisation 1 (n=82)
Randomisation 1+2 (n=48)
Fig 1 | Flow chart of participation in UK Turner Study according to treatment groups, completions, and withdrawals. *Withdrawn before 12 years of age (that is,
randomised only at randomisation 1 to oxandrolone or placebo). †Aged ≥12.25 years at recruitment; oestrogen treatment started at 14 years with no
randomisation. ‡Withdrawn after 12 years of age (that is, randomised at randomisation 1 to oxandrolone or placebo and at randomisation 2 if oestrogen
treatment needed)
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ment dose once pubertal induction was completed.
White, uncoated, flat bevelled edge placebo tablets
(7and5mmindiameter)(EssentialNutrition,Brough,
UK) were specially manufactured to match the size,
weight, and appearance of oxandrolone 2.5 mg and
ethinylestradiol 2 µg tablets respectively. The study’s
central pharmacy (Royal Hospital for Sick Children,
Glasgow, UK) supplied all tablets in a double blind,
placebo controlled fashion; only staff at the British
Society for Paediatric Endocrinology and Diabetes
Clinical Trials Unit and the central distributing phar-
macy were not blinded to treatment allocations.
Oxandrolone supplies
In 2004 and 2008, the sole European manufacturer of
oxandrolone2.5mgceasedproduction,resultingin34
participants in 2004 and 11 in 2008 temporarily sus-
pending active oxandrolone treatment (mean dura-
tion: 2004, 52 days; 2008, 163 days). In 2008, the
decision was taken to terminate the treatment arm
forthwith, resulting in eight participants stopping
oxandrolone treatment prematurely.
Study procedures
At clinic visits every four to six months, height was
measured with a Harpenden stadiometer to the last
completed 1 mm and converted to an SD score by
using the British 1990 reference.
22 Radiographs of the
leftwristwereobtainedannually,andasingleobserver
(WFP) analysed them for bone age estimation accord-
ing to the Tanner Whitehouse II method.
23 Biochem-
ical analyses followed local protocols, and the results
were reported centrally.
Standardised pharmacovigilance procedures were
followed,withrecordingofadverseeventsorreactions
at each visit and subsequent review by the Data and
Safety Monitoring Group. Data collection ceased if
participants withdrew consent, although we included
previously collected data in the analysis.
Statistical methods
The primary outcome was final height, defined as
height velocity less than 1 cm/year and bone age at
least 15.5 years. Secondary outcomes were maximum
height (that is, the most recently available height), age
ofattainingfinalheight,andthethreesummarygrowth
parameters from the SITAR analysis described below.
Assuming a standard deviation of 5 cm, we needed
50 girls in each group to detect a difference between
groups in mean final height of 2.8 cm with 80%
power at 5% significance—a total of 100 patients. The
study was not formally powered to detect a significant
interaction between the two randomisations. In the
event, more than 100 patients were recruited, but
fewer than 100 were followed up to final height.
Table 1 |Characteristics of participants at enrolment, maximum height, and final height, according to treatment group. Values are mean (SD) unless stated
otherwise
Characteristics
Randomised to
oestrogen at 12 years
Randomised to
oestrogen at 14 years
Late group (oestrogen at
14 years) No oestrogen needed
Total Oxandrolone Placebo Oxandrolone Placebo Oxandrolone Placebo Oxandrolone Placebo
At enrolment* (n=12) (n=17) (n=14) (n=17) (n=10) (n=11) (n=11) (n=7) (n=99)
Median (range) age
at diagnosis (years)
0.1 (0-9.8) 4.6 (0-9.2)† 4.5 (0-9.8) 1.5 (0-9.8) 2.8 (0-12.7) 3.1 (0-13.4) 6.6 (0.7-10.4) 8.3 (0.5-10.1) 3.8 (0-13.4)
Age (years) 10.1 (1.3) 9.4 (0.7) 9.5 (1.4) 9.7 (1.2) 12.5 (0.4) 12.8 (0.4) 9.8 (1.1) 9.8 (1.4) 10.3 (1.6)
Height (cm) 126.4 (6.9) 120.5 (5.9) 121.6 (6.7) 125.7 (6.7) 137.2 (6.8) 133.9 (4.2) 124.4 (7.4) 125 (9.2) 126.2 (8.3)
Height SD score −1.9 (0.7) −2.4 (0.8) −2.2 (0.8) −1.8 (0.8) −2.1 (0.9) −2.9 (0.6) −2.1 (0.9) −2.0 (0.8) −2.1 (0.8)
Target height (cm) 163.8 (3.4) 162.0 (4.0) 161.5 (4.1) 163.1 (5.5) 165.1 (2.6) 161.6 (2.9) 163.0 (4.7) 162.6 (4.5) 162.7 (4.1)
Median (range) age
at growth hormone start
(years)
5.4 (4.0-10.2) 7.3 (2.4-10.1) 6.1 (2.2-10.5) 4.2 (2.4-9.6) 8.3 (4.5-12.8) 9.5 (4.0-13.8) 6.0 (3.2-10.9) 8.7 (1.7-10.3) 6.4 (1.7-13.8)
Median (range) duration of
growth hormone before
oestrogeninduction(years)
6.6 (1.8-8.0) 4.7 (1.9-9.6) 7.9 (3.5-11.9) 9.8 (4.4-11.6) 5.7 (1.2-9.5) 4.5 (0.2-10.0) –– 6.6 (0.2-11.9)
At maximum height‡ ‡ (n=11) (n=17) (n=13) (n=15) (n=9) (n=10) (n=10) (n=7) (n=92)
Age (years) 16.2 (1.4) 15.9 (1.2) 16.2 (1.5) 16.8 (1.0) 17.0 (1.0) 17.9 (1.0) 14.9 (0.8) 15.0 (0.9) 16.3 (1.4)
Height (cm) 154.4 (3.9) 147.2 (7.0) 153.0 (8.1) 152.0 (6.8) 155.3 (4.3) 148.9 (6.0) 151.9 (6.0) 150.2 (6.2) 151.4 (6.7)
Height SD score −1.4 (0.7) −2.5 (1.2) −1.5 (1.1) −1.9 (1.1) −1.3 (0.7) −2.4 (1.0) −1.5 (1.0) −1.8 (0.9) −1.8 (1.1)
Change in height SD score 0.6 (0.5) −0.1 ( 0.6) 0.7 (1.0) −0.1 ( 0.7) 0.7 (0.8) 0.5 ( 0.8) 0.5 (1.0) 0.2 (0.7) 0.3 (0.8)
At final height§ § (n=11) (n=14) (n=10) (n=13) (n=9) (n=10) (n=9) (n=6) (n=82)
Age (years) 16.2 (1.4) 16.2 (0.8) 16.8 (0.8) 17.2 (0.9) 17.0 (1.0) 17.9 (1.0) 15.0 (0.9) 15.2 (1.0) 16.5 (1.3)
Height (cm) 154.4 (3.9) 147.0 (7.4) 155.1 (4.1) 153.1 (6.7) 155.3 (4.3) 148.9 (6.0) 151.8 (6.4) 149.4 (6.4) 151.8 (6.4)
Height SD score −1.4 ( 0.7) −2.6 (1.2) −1.4 (0.7) −1.7 (1.1) −1.3 (0.7) −2.4 (1.0) −1.5 (1.1) −2.0 (0.9) −1.8 (1.0)
Change in height SD score 0.6 (0.5) −0.3 (0.5) 0.9 (0.9) −0.1 (0.8) 0.7 (0.8) 0.5 ( 0.8) 0.3 (1.0) 0.1 (0.9) 0.3 (0.8)
*Excluding 7 withdrawn participants: 1 immediately after enrolment, so no baseline data available; 6 before age 12, who were randomised only at randomisation 1 (4 oxandrolone, 2
placebo).
†Excluding 2 antenatal diagnoses.
‡Excluding 14 withdrawn participants (that is, including 82 at final height and 10 yet to reach final height).
§Excluding 14 withdrawn participants and 10 yet to reach final height.
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separately by using multiple regression. We also
adjusted randomisation 2 (timing of pubertal induc-
tion) for randomisation 1 (oxandrolone) and tested
for an interaction.
In addition, we applied SITAR (superimposition by
translation and rotation), a novel method of growth
curve analysis, to the data.
24 SITAR transforms indivi-
dual growth curves so that they become essentially the
same as each other and, when superimposed, define
theaveragesummarycurve.Toachievethis,eachindi-
vidual curve is suitably altered in three distinct ways:
the curve is shifted up/down (a measure of the child’s
sizeincm)andleft/right(ameasureofgrowthtempoin
years), and the age axis is stretched/squashed (a mea-
sure of percentage velocity). Size, tempo, and velocity
are thus participant specific random effects summaris-
ing how each girl’s curve differs from the average
curve. The effects of the randomisations can be
explored by comparing the values of the random
effects by trial arm. Equally, separate summary curves
can be constructed for each trial arm.
RESULTS
One hundred and six girls with Turner’s syndrome
were recruited from 36 UK hospitals between 1999
and2003,ofwhom14withdrew(fourofthembecause
of early organisational errors), leaving 92 to complete
thestudy(fig1).Thebreakdownofkaryotypeswas45,
X (39), 45,X/46,XX (18), 45,X/46,XrX (9), complex
mosaics containing three or more cell lines (8),
45,X/46,XiX (7), 45,X/45,XY (7), 46,XX including a
structural abnormality of second X (7), 45,X/46,XY
including a structural abnormality of Y (3), 45,X/46,XX
including a structural abnormality of second X (3),
45,X/47,XXX (2), and other (3).
All 106 participants were randomised at or after
9 years of age to oxandrolone or placebo (randomisa-
tion 1), and 60 were also randomised at 12 years to
early or late induction of puberty (randomisation 2).
Of the 46 girls not randomisedat 12 years,21 enrolled
after12years(thelategroup),18hadspontaneouspub-
erty, and seven had withdrawn before the age of
12 years.
Final and maximum height
Table 1 shows participants’ characteristics at enrol-
ment, at maximum height, and at final height by treat-
mentgroup.At thetimeofwriting,82participantshad
attained a mean final height of 151.8 (SD 6.4) cm, and
10 others continued growing. Table 2 shows details of
final height and maximum height according to the
study’s two randomisations.
By twice randomised group, the mean final heights
were placebo/early induction 147.0 cm, placebo/late
induction 153.1 cm, oxandrolone/early induction
154.4 cm, and oxandrolone/late induction 155.1 cm
(table 1). Table 3 summarisesthe results of the rando-
mised comparisons. For randomisation 1, final height
was significantly greater with oxandrolone than pla-
cebo (4.6 cm, 95% confidence interval 1.9 to 7.2;
P=0.001). Similarly, for randomisation 2, final height
was significantly greater with pubertal induction at
14 years than at 12 years (3.8 cm, 0.0 to 7.5; P=0.05).
However, the positive effects of oxandrolone and
late induction were not additive. Among girls pre-
viously randomised to oxandrolone, the effect of late
inductioncomparedwithearlyinductionwasclinically
insignificant(+0.7cm);intheplacebogroup,however,
SITAR adjusted age (years)
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Fig 2 | Individual height growth curves according to randomisation 1: unadjusted (left) and SITAR adjusted (right)
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induction (table 3, interaction). The two treatments
together were thus no more effective than either one
alone, as shown by the substantial and close to signifi-
cant negative interaction. The mean effect on final
height of oxandrolone, late induction of puberty, or
both compared with placebo and early induction was
+7.1cm(thatis,the meanfinalheightinthe combined
oxandrolone/early, oxandrolone/late, and placebo/
late groups compared with the placebo/early group),
which is appreciably larger than the effects for either
randomisation alone (table 3, combination). This was
because the randomisation analyses compared inter-
vention and control groups in which half of each con-
trol group had received an effective intervention from
the other randomisation, thus reducing the apparent
effect size. The standard deviation for the combined
group was 5.1 cm, rather less than the 7.4 cm for the
placebo/earlyinductiongroup(P=0.1),suggestingthat
treatment preferentially benefited the shortest girls.
Table 3 also includes the results for maximum
height, based on the 92 girls still in the trial. The oxan-
drolone effect of +4.3 cm (P=0.002) was similar to that
for final height (+4.6 cm), and the late induction effect
of +2.4 cm (P=0.2) was appreciably smaller than the
+3.8 cm for final height. The age of attainment of
final height was similar for oxandrolone and placebo
(16.2 v 16.7 years; P=0.1) and later, by design, for late
versus early induction (16.9 v 16.1 years; P=0.009).
SITAR analysis of height curves
Weapplied theSITAR analysisto the105 participants
with at least one height measurement (one girl in the
control group withdrew immediately after randomisa-
tion 1). Figure 2 shows individual height curves un-
adjusted (left panel) and SITAR adjusted with the
summary curve (right panel). The curves are labelled
according to randomisation 1, and the oxandrolone
curves tend to be above and to the left of the placebo
curves.
The SITAR adjustment process estimated the size,
tempo, and velocity parameters for each participant,
which when applied to their curves made them all
very similar, with a residual standard deviation of
0.6 mm around the summary curve (fig 2, right
panel). Comparison of the mean values of the para-
meters by trial arm showed differences in size (oxan-
drolone v placebo +2.6 cm; P=0.02) but not tempo
(−0.3 years; P=0.1), and the mean velocity was drama-
tically greater for oxandrolone (difference +23%, SE
Table 2 |Final height and maximum height data for participants randomised twice, according
to randomisation 1 (oxandrolone/placebo) and randomisation 2 (pubertal induction at 14/
12 years). Values are mean (SD)
Measurement
Randomisation 1 Randomisation 2
Oxandrolone Placebo
Induction at
14 years
Induction
at 12 years
Final height (n=39) (n=43) (n=23) (n=25)
Age (years) 16.2 (1.4) 16.7 (1.3) 16.9 (0.8) 16.1 (1.2)
Height (cm) 154.2 (4.7) 149.6 (7.0) 154.0 (5.7) 150.2 (7.1)
Height SD score −1.4 (0.7) −2.2 (1.1) −1.6 (0.9) −2.1 (1.2)
Change in height SD score 0.7 (0.8) 0.0 (0.8) 0.3 (1.0) 0.1 (0.7)
Maximum height (n=43) (n=49) (n=28) (n=28)
Age (years) 16.0 (1.4) 16.5 (1.3) 16.6 (1.2) 16.0 (1.3)
Height (cm) 153.6 (5.9) 149.3 (6.8) 152.4 (7.3) 150.0 (6.9)
Height SD score −1.4 (0.8) −2.2 (1.1) −1.7 (1.1) −2.0 (1.1)
Change in height SD score 0.6 (0.8) 0.0 (0.7) 0.3 (0.9) 0.2 (0.7)
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Fig 3 | SITAR fitted summary height curves by trial arm for randomisation 1 (left) and randomisation 2 (right)
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agescaleintheoxandrolonearmwasforeshortenedby
23%, increasing the velocity and making the oxandro-
lone curve correspondingly steeper than the placebo
curve, although the age of final height was no earlier.
This effect is seen in figure 3 (left panel), which shows
SITAR summary curves calculated separately for
oxandrolone and placebo. The two curves cross at
10 years, and height velocity is consistently greater in
the oxandrolone arm.
Figure3(rightpanel)showsthecorrespondingcom-
parisonofsummaryheightcurvesforrandomisation2,
late versus early induction. The differences here were
smaller, the curves diverging only after 14 years; the
late versus early comparisons for size (+2.2 cm) and
velocity (−9%) were statistically insignificant (P>0.1),
whereas tempo was slightly delayed in the late induc-
tion arm (+0.4 years; P=0.06).
Adverse events
Between 1999 and 2009, 197 adverse events were
reported; none of them were suspected to be unex-
pected serious adverse reactions. Ten were classified
as serious adverse events, as they involved admission
to hospital for procedures including appendicectomy
and ear, nose, and throat surgery (for example, grom-
met (ventilation tube) insertion). Four adverse events
could have been related to oxandrolone or ethinyles-
tradiol:acne ina 15 yearold(allstudydrugswere con-
tinued, and randomisation was later revealed as
oxandrolone and pubertal induction at 14 years);
persistenthypertensionina13yearold(oxandrolone/
placebo was stopped and antihypertensive treatment
started, blood pressure normalised, and oxandro-
lone/placebo treatment was restarted; the randomisa-
tion was later revealed as oxandrolone and pubertal
induction at 12 years); abnormal liver function in a
16 year old (the participant was at near final height
and elected to stop growth promoting treatment; ran-
domisation was later revealed as oxandrolone and
pubertal induction at 14 years); and episodic “hot
flushes” in a 15 year old (all study drugs were contin-
ued; randomisation was later revealed as placebo and
pubertal induction at 14 years). No virilisation was
reported; in particular, no voice deepening or clitoro-
megaly was noted.
DISCUSSION
This randomised controlled trial of growth promoting
treatmentinTurner’ssyndromeshowedaclearbenefit
to final height of oxandrolone treatment and of intro-
ducingethinylestradiolforpubertalinductionatage14
rather than 12 years.
Comparison with other studies
This positive effect of oxandrolone on final height
compares favourably with previous studies.
561112
Early studies using high doses of oxandrolone had to
reduce or stop treatmentafterreports ofvirilisation,
612
and others showed little or no effect of
oxandrolone.
1314 However, they were retrospective
indesignandvariedintreatmentprotocol.Incontrast,
the UK Turner Study used a prospective placebo con-
trolled design, with consistent doses of oxandrolone
throughout. A recent Dutch trial comparing growth
hormone with two doses of oxandrolone (0.03 and
0.06 mg/kg/day) reported that the lower dose signifi-
cantly increased adult “height gain” compared with
placebo,whereasthehigherdosedidnot.
15Incontrast,
the final height in both oxandrolone groups was only
approximately 1 cm greater than placebo (156.7 cm
and 156.5 cm versus 155.6 cm). The more favourable
outcomeintheUKstudycouldberelatedtoearlierage
at starting growth hormone therapy (6.4 v ~9 years)
and also to the lower doses of oxandrolone given in
the UK study (0.05 mg/kg/day, maximum 2.5 mg
daily) compared with the 0.06 mg/kg/day arm of the
Dutch study.
No adverse events directly attributable to oxandro-
lone were reported in the UK Turner Study; in parti-
cular, no virilisation was reported. Although
Table 3 |Effects of two randomisations, their interaction, and their combination, on mean final height and mean maximum
height
Randomisation Mean/mean difference (SE) Mean/mean difference (SE) Difference (95% CI) P value
Randomisation 1 (Oxandrolone) (Placebo)
Final height (cm) 154.2 (0.8) (n=39) 149.6 (1.1) (n=43) 4.6 (1.9 to 7.2) 0.001
Maximum height (cm) 153.6 (0.9) (n=43) 149.3 (1.0) (n=49) 4.3 (1.6 to 6.9) 0.002
Randomisation 2 (Induction at 14 years) (Induction at 12 years)
Final height (cm) 154.0 (1.2) (n=23) 150.2 (1.4) (n=25) 3.8 (0.0 to 7.5) 0.05
Maximum height (cm) 152.4 (1.4) (n=28) 150.0 (1.3) (n=28) 2.4 (−1.5 to 6.2) 0.2
Interaction of R1 by R2* (Oxandrolone
(14 years−12 years))
(Placebo (14 years−12 years))
Final height (cm) 0.7 (1.7) (n=21) 6.2 (2.7) (n=27) −5.5 (−12.4 to 1.4) 0.1
Maximum height (cm) −1.5 (2.5) (n=24) 4.7 (2.5) (n=32) −6.2 (−13.5 to 1.2) 0.1
Combination of R1 and R2† † (Oxandrolone OR 14 years) (Placebo AND 12 years)
Final height (cm) 154.1 (0.9) (n=34) 147.0 (2.0) (n=14) 7.1 (3.4 to 10.8) <0.001
Maximum height (cm) 153.0 (1.0) (n=39) 147.2 (1.7) (n=17) 5.8 (1.9 to 9.7) 0.004
*Summary statistics under oxandrolone and placebo are differences in mean height (SE) between corresponding 14 year and 12 year induction
groups.
†Groups: oxandrolone/12 years, oxandrolone/14 years, and placebo/14 years combined; and placebo/12 years.
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acne,hypertension,andabnormalliverfunction,caus-
alitycannotbeassumedasthesearecommonlyseenin
Turner’s syndrome.
2526 By contrast, the Dutch study
reported virilisation in 15/36 girls receiving 0.06 mg/
kg/day, which was severe enough for treatment to be
discontinued in seven. However, patients receiving
placebo also reported virilisation, and how these
events were assessed is unclear.
15 Furthermore, the
maximum daily dose of 2.5 mg used in the UK study
irrespective of body weight could account for the
absence of reported virilisation.
The UK Turner Study has also shown a positive
effect on final height of introducing ethinylestradiol at
age14ratherthan12years,consistentwiththeeffectof
oestrogen on epiphyseal fusion and supporting pre-
viouspublishedassociationsbetweendelayedpubertal
induction and increased height.
61318 Since 1999,
however,concernhasbeenexpressedaboutthepoten-
tialcardiovascular,skeletal,reproductive,andpsycho-
logical consequences of prolonged oestrogen
deficiency.
1927-29 The finding that oxandrolone allows
timelypubertalinductionisthusattractiveandinkeep-
ing with other work.
30-34 This study shows that oxan-
drolone increases height velocity throughout the
growing period yet does not materially advance the
age of final height.
However,whereasbothoxandroloneandlateinduc-
tion have been shown to increase final height, the two
effects were not additive, so that giving either is bene-
ficial but giving both is no better. One possible expla-
nation for this is that there is a “ceiling” for the extra
height available from growth promoting strategies in
Turner’s syndrome.
The subset of participants who were randomised
twice and received oxandrolone had a larger “gain”
in final height than did those who did not need any
oestrogen treatment, whether they received oxandro-
loneornot.Thenumbersweretoosmalltoallowmore
detailed analysis, but we speculate that the girls who
showed spontaneous puberty would have fused their
epiphyses earlier than the other girls, which may
have resulted in a less favourable final height.
Strengths and limitations of study
This randomised controlled trial has examined a large
cohort ofpatientstreated systematically over a 10 year
period. Treatment has been well tolerated, such that
dropout rates were low (14/106) and the mean final
height for the group to date (151.8 cm) is well above
the target of 150 cm for girls with Turner’s syndrome
treated with growth hormone.
63536
The number of girls who had completed the study
and achieved final height at the time of analysis (n=82)
fell short of the target sample size of 100. Even when
the remaining girls complete the study, the number
evaluable at final height will still only be 92. Despite
this, however, the group of 82 girls has been sufficient
to show positive effects of oxandrolone and delayed
pubertal induction, and the addition of the 10 girls
yet to complete is unlikely to materially alter the out-
come. However, the failure to achieve the target sam-
ple size may have limited the ability to detect an
interaction between the two randomisations.
Unfortunately, the break in production of oxandro-
lone 2.5 mg tablets twice led to deviations from the
protocol. Placebo tablets were unavailable for other
oxandrolone preparations, and eventually the difficul-
ties in supply led to the early termination of the treat-
ment arm. Therefore, the results may underestimate
the true effect of oxandrolone. Even so, they make a
strong case for reintroduction of oxandrolone manu-
facture in Europe or, failing that, affordable importa-
tion, as costs of supplies from elsewhere are
prohibitive.
Girls with mosaic Turner’s karyotypes were
included in the study. With a larger sample size, the
effect of different karyotypes, with varying haploinsuf-
ficiencyoftheSHOXregion,onheightoutcomecould
be examined. However, the group sizes of those who
were randomised twice and attained final height were
too small to allow further breakdown by karyotype.
Ameasureofbonemineraldensitywasnotincluded
in the study protocol and would have provided valu-
ableinformation.Althoughitsvalueisnowrecognised
in this patient group, the necessary scanning equip-
ment was not routinely available at all participating
centres when the study started.
Conclusions and policy implications
Oxandrolone has a positive effect on final height, as
has inducing puberty at age 14 rather than 12 years.
However, doing both offers no added benefit. We
recommend, therefore, that when growth promotion
is being considered in girls with Turner’s syndrome,
families are offered oxandrolone as an alternative to
late pubertal induction.
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